GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » EV-to-EBIT

Genmab A/S (Genmab A/S) EV-to-EBIT : 16.99 (As of Apr. 28, 2024)


View and export this data going back to . Start your Free Trial

What is Genmab A/S EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genmab A/S's Enterprise Value is $13,894 Mil. Genmab A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $818 Mil. Therefore, Genmab A/S's EV-to-EBIT for today is 16.99.

The historical rank and industry rank for Genmab A/S's EV-to-EBIT or its related term are showing as below:

GNMSF' s EV-to-EBIT Range Over the Past 10 Years
Min: -320.6   Med: 41.97   Max: 77379.07
Current: 17.55

During the past 13 years, the highest EV-to-EBIT of Genmab A/S was 77379.07. The lowest was -320.60. And the median was 41.97.

GNMSF's EV-to-EBIT is ranked worse than
65.24% of 443 companies
in the Biotechnology industry
Industry Median: 8.19 vs GNMSF: 17.55

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Genmab A/S's Enterprise Value for the quarter that ended in Dec. 2023 was $16,621 Mil. Genmab A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $818 Mil. Genmab A/S's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 4.92%.


Genmab A/S EV-to-EBIT Historical Data

The historical data trend for Genmab A/S's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S EV-to-EBIT Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.79 24.58 39.16 24.48 20.03

Genmab A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.48 21.85 24.56 25.82 20.03

Competitive Comparison of Genmab A/S's EV-to-EBIT

For the Biotechnology subindustry, Genmab A/S's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genmab A/S's EV-to-EBIT falls into.



Genmab A/S EV-to-EBIT Calculation

Genmab A/S's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=13894.474/817.936
=16.99

Genmab A/S's current Enterprise Value is $13,894 Mil.
Genmab A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $818 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab A/S  (OTCPK:GNMSF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Genmab A/S's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=817.936/16621.03228
=4.92 %

Genmab A/S's Enterprise Value for the quarter that ended in Dec. 2023 was $16,621 Mil.
Genmab A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $818 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab A/S EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Genmab A/S's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (Genmab A/S) Business Description

Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (Genmab A/S) Headlines

From GuruFocus